ClostraBio develops dietary supplements and a platform for targeted metabolite delivery to enhance gut health and restore intestinal barrier function. The company focuses on treating food allergies and inflammatory bowel disease by improving innate immunity and gut integrity.
Funding
$14.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PIFounders
Product
Problem
Current treatments for inflammatory bowel disease (IBD) and food allergies often fail to fully restore intestinal barrier function and innate immunity, leading to persistent symptoms and reduced quality of life. Existing dietary supplements lack targeted delivery mechanisms, limiting their effectiveness in delivering beneficial metabolites to the gut.
Solution
ClostraBio is developing a platform for targeted metabolite delivery to enhance gut health and restore intestinal barrier function. Their approach focuses on improving innate immunity and gut integrity to directly treat diseases of the gut and food allergies. The company is creating both a dietary supplement and a "plug-n-play" platform designed for the targeted delivery of bacterial metabolites. This targeted approach aims to maximize the therapeutic impact of beneficial compounds within the gut.
Target Audience
The primary target audience includes individuals suffering from inflammatory bowel disease (IBD) and food allergies, as well as healthcare professionals seeking innovative solutions for gut health management.
Features
- Targeted delivery of bacterial metabolites to the gut
- Focus on restoration of intestinal barrier-protective function
- Enhancement of innate immunity
- Development of dietary supplements for gut health
- "Plug-n-play" platform for metabolite delivery